STOCK TITAN
  1. Home
  2. News
  3. XOMA

XOMA Royalty Corporation - XOMA STOCK NEWS

Welcome to our dedicated page for XOMA Royalty Corporation news (Ticker: XOMA), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty Corporation stock.

XOMA Corporation (NASDAQ: XOMA) is a biotechnology royalty aggregator that plays a pivotal role in accelerating the development of groundbreaking therapeutic candidates. With an extensive portfolio of over 70 assets, XOMA acquires potential future economics associated with pre-commercial and commercial therapeutic candidates licensed to pharmaceutical or biotech companies. This unique model enables XOMA to provide non-dilutive, non-recourse funding to its partners, helping them advance their internal drug candidates or cater to general corporate needs.

Notably, XOMA has pioneered in the discovery and development of antibody therapeutics, leading to over 20 licenses producing milestone and royalty payments in the future. One key asset in their portfolio is X358, an allosteric monoclonal antibody aimed at treating hyperinsulinism by reducing insulin receptor activity.

XOMA has recently expanded its portfolio through strategic acquisitions. In January 2024, the company acquired an economic interest in DSUVIA® (sufentanil sublingual tablet) from Talphera, Inc., for $8 million. DSUVIA® is an FDA-approved pain management option used in supervised medical settings. The agreement stipulates that XOMA will receive all royalties and milestones related to DSUVIA® until $20 million is accrued. Subsequently, royalties will be shared between XOMA and Talphera.

Further broadening its portfolio, XOMA acquired Kinnate Biopharma in April 2024, bringing additional assets into their royalty pipeline. Kinnate’s lead candidates include investigational pan-RAF inhibitor exarafenib and FGFR inhibitor KIN-3248, both targeting cancers with specific genetic alterations.

In April 2024, XOMA announced a $9 million milestone following the FDA approval of Day One Biopharmaceuticals’ OJEMDA™ (tovorafenib), designed to treat pediatric low-grade glioma harboring BRAF alterations. This approval marks a significant addition to XOMA's cash flow and royalty income.

Additionally, XOMA's economic interest in three of Daré Bioscience's women's health products, including the FDA-approved XACIATO™ (clindamycin phosphate) vaginal gel, Ovaprene®, and Sildenafil Cream, 3.6%, signifies their commitment to addressing underrepresented therapeutic areas with significant growth potential.

As of their latest financial results, XOMA reported strong cash reserves and a growing portfolio of commercial and development-phase assets, ensuring long-term sustainability and value creation for shareholders. The company’s disciplined approach to capital deployment and strategic acquisitions highlights its commitment to enhancing human health through biotechnology advancements.

News

XOMA to Present at Upcoming Investor Conferences in March

Rhea-AI Summary
XOMA Corporation announces participation in upcoming investor conferences in March 2024, with key executives presenting at TD Cowen Health Care Conference and Leerink Partners Global Biopharma Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
conferences
-
News

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

Rhea-AI Summary
XOMA Corporation announced the acquisition of Kinnate Biopharma Inc. for a base cash price of $2.3352 per share, potentially adding $9.5 million in cash to its balance sheet. The deal includes a contingent value right (CVR) and aims to enhance XOMA's royalty portfolio. The acquisition is expected to close in April 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.28%
Tags
acquisition
-
News

XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition

Rhea-AI Summary
XOMA Corporation acquires economic interest in DSUVIA® from Talphera, Inc. for $8 million, with a 15% royalty on commercial sales and a significant portion of the 75% royalty from U.S. Department of Defense purchases. XOMA is entitled to no less than 50% of the potential $116.5 million in milestone payments. DSUVIA® received Milestone C approval from the U.S. Department of Defense for use in U.S. Army sets, kits, and outfits (SKOs) and was added to the DoD Joint Deployment Formulary in September 2020. XOMA will receive 100% of all royalties and milestones related to DSUVIA® sales until the Company receives $20 million, after which XOMA fully retains the 15% royalty associated with DSUVIA® commercial sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
acquisition
News

FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx

Rhea-AI Summary
XOMA Corporation (NASDAQ: XOMA) announced that the FDA has accepted Zevra Therapeutics' New Drug Application for arimoclomol, a first-in-class therapy for Niemann-Pick disease type C (NPC), with a PDUFA target action date of June 21, 2024. XOMA will make a $1 million milestone payment to LadRx based on the FDA's acceptance. The company previously paid LadRx a $5 million upfront payment and acquired a mid-single digit royalty on arimoclomol's commercial sales, with potential milestone payments of up to $52.6 million, net, from Zevra. The transaction also included a royalty rate on commercial sales of aldoxorubicin and potential payments of up to $343 million in development and commercial milestones from ImmunityBio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.89%
Tags
clinical trial
-
News

LadRx Issues 2024 Update to Shareholders

Rhea-AI Summary
LadRx Corporation (LADX) announces FDA acceptance of arimoclomol NDA triggering a $1 million payment from XOMA. Anticipated milestones for 2024 include first commercial sale of arimoclomol and entering first-in-human studies of LADR-7.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.8%
Tags
none
-
News

XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

Rhea-AI Summary
XOMA Corporation (XOMA) announced the appointment of Owen Hughes as Chief Executive Officer and Jack L. Wyszomierski as Chairman of the Board. Hughes has been serving as XOMA's Executive Chairman and Interim CEO since January 1, 2023. The Board aims to establish XOMA as a premier biotech royalty aggregator, focusing on accelerating growth and maximizing value for stockholders. The company's growing cash receipts and maturing portfolio reflect significant inflection points within its established royalty and milestone acquisition strategy. XOMA also boasts the largest cash balance in its history.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.5%
Tags
management
News

XOMA Announces Stock Repurchase Program of up to $50 Million

Rhea-AI Summary
XOMA Corporation (Nasdaq: XOMA) announces its first stock repurchase program, authorizing the purchase of up to $50 million of common stock through January 2027. The company aims to maximize shareholder value through prudent capital allocation, leveraging future cashflow streams of its growing royalty portfolio to generate superior risk-adjusted, non-correlated returns for investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.92%
Tags
buyback
-
News

XOMA Declares Quarterly Preferred Stock Dividends

Rhea-AI Summary
XOMA Corporation (Nasdaq: XOMA) announced cash dividends for its Series A and Series B Cumulative Preferred Stock. Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) will receive a cash dividend of $0.53906 per share, while holders of depositary shares for XOMA’s 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO) will receive a cash dividend of $0.52344 per depositary share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
dividends
-
News

XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties

Rhea-AI Summary
XOMA Corporation (Nasdaq: XOMA) secures $140 million non-dilutive, non-recourse, royalty-backed loan from Blue Owl Capital Inc. (NYSE: OWL) to fund stock repurchases and additional royalty and milestone acquisitions. The loan is repayable over a 15-year period at a fixed interest rate of 9.875% per year, with the option to draw an additional $10 million based on VABYSMO® (faricimab) sales. XOMA has also issued warrants to purchase up to 120,000 shares of its common stock to Blue Owl at implied premiums of 122%, 170%, and 217% to the closing stock price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.23%
Tags
none
News

XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value

Rhea-AI Summary
XOMA Corporation reported $6.6 million in cash receipts, a NDA filing, and anticipated Phase 3 program initiation, with third-quarter 2023 revenues of $0.8 million and G&A expenses of $6.4 million. The company received a $4.9 million cash payment from Roche and earned a $5 million milestone related to the FDA's acceptance of Day One Biopharmaceuticals' NDA for tovorafenib.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.44%
Tags
earnings

FAQ

What is the current stock price of XOMA Royalty Corporation (XOMA)?

The current stock price of XOMA Royalty Corporation (XOMA) is $27.13 as of December 20, 2024.

What is the market cap of XOMA Royalty Corporation (XOMA)?

The market cap of XOMA Royalty Corporation (XOMA) is approximately 302.6M.

What does XOMA Corporation do?

XOMA Corporation is a biotechnology royalty aggregator that acquires potential future economics from pre-commercial and commercial therapeutic candidates licensed to pharmaceutical or biotech companies.

What is XOMA’s business model?

XOMA provides non-dilutive, non-recourse funding to biotech companies in exchange for future economic rights to their therapeutic candidates, helping these companies advance their drug development.

What recent acquisitions has XOMA made?

In 2024, XOMA acquired an economic interest in DSUVIA® from Talphera, Inc., and Kinnate Biopharma, expanding its portfolio with new commercial and development-phase assets.

What are some key assets in XOMA's portfolio?

Key assets include DSUVIA® for pain management, OJEMDA™ for pediatric low-grade glioma, and women's health products like XACIATO™, Ovaprene®, and Sildenafil Cream from Daré Bioscience.

How does XOMA generate revenue?

XOMA generates revenue through milestone and royalty payments from the assets and therapeutic candidates it holds economic interests in.

What is the significance of XOMA’s investment in X358?

X358 is an allosteric monoclonal antibody that reduces insulin receptor activity, potentially having a major impact on the treatment of hyperinsulinism.

How does XOMA support biotech companies?

XOMA supports biotech companies by providing non-dilutive funding, allowing them to advance their drug candidates or support corporate initiatives without giving up equity.

What was the financial impact of XOMA’s acquisition of DSUVIA®?

XOMA will receive 100% of royalties and milestones from DSUVIA® sales until $20 million is accrued, after which royalties are shared with Talphera.

Who are some of XOMA’s partners?

XOMA has partnerships with various biotech and pharmaceutical companies, including Talphera, Alora Pharmaceuticals, Viracta Therapeutics, and Daré Bioscience.

What are XOMA's future plans for growth?

XOMA plans to continue its disciplined approach to capital deployment, acquiring economic interests in promising therapeutic candidates, and building a sustainable, cash-generating royalty portfolio.

Stock XOMA logo
XOMA Royalty Corporation

Nasdaq:XOMA

XOMA Rankings

#3524 Ranked by Market Cap
N/A Ranked by Dividends

XOMA Stock Data

302.58M
11.68M
0.84%
65.62%
1.11%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
EMERYVILLE